公开(公告)号：US20240358830A1

公开(公告)日：2024-10-31

申请号：US18684155

申请日：2022-08-19

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Young Jik Kwon ,  Jee Young Chung

IPC分类号： A61K39/00 ,  A61K35/15 ,  A61K39/39 ,  A61P35/00 ,  C12N5/16

CPC分类号： A61K39/4622 ,  A61K35/15 ,  A61K39/39 ,  A61K39/4615 ,  A61K39/4644 ,  A61P35/00 ,  C12N5/163

摘要： The disclosure provides compositions, preparations, and methods comprising cell-derived vesicles induced using a blebbing agent from a hybridoma of a dendritic cell and a target cell, and uses thereof, including as a means to modulate a subject's immune system.

公开(公告)号：US20240325534A1

公开(公告)日：2024-10-03

申请号：US18580533

申请日：2022-07-19

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： Neil Sheppard ,  Yi Wen

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30

CPC分类号： A61K39/4644 ,  A61K39/4611 ,  A61K39/4631 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/283 ,  C07K16/30 ,  A61K2239/15 ,  A61K2239/21 ,  A61K2239/22 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/033

摘要： The present invention provides compositions and methods comprising chimeric antigen receptors (CARs) wherein the ‘Signal 1’ has been optimized, for example wherein the CAR comprises an intracellular domain comprising a truncated version of CD3ζ, a FcRγ or portion thereof, or a hybrid of CD3ε and CD3ζ. Compositions and methods of treatment are also provided.

公开(公告)号：US20240279318A1

公开(公告)日：2024-08-22

申请号：US18560661

申请日：2022-05-31

申请人： Nanjing Legend Biotech Co., Ltd.

发明人： Mingxin LI ,  Zhigang LI ,  Shuai YANG ,  Ming ZENG ,  Sujuan Wang ,  Lan XU ,  Shu Wu

IPC分类号： C07K16/18 ,  A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783

CPC分类号： C07K16/18 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/4644 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/2833 ,  C12N5/0636 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/02 ,  C12N2510/00

摘要： This disclosure relates to antibodies, antigen-binding fragments, protein constructs, and chimeric antigen receptors that bind to a complex comprising an AFP peptide and an MHC molecule, and the uses thereof.

公开(公告)号：US20240059787A1

公开(公告)日：2024-02-22

申请号：US18245879

申请日：2021-09-18

申请人： Feng Wang-Johanning ,  Gary Johanning

发明人： Feng Wang-Johanning ,  Gary Johanning

IPC分类号： C07K16/30 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

CPC分类号： C07K16/30 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/4644 ,  A61K39/464838 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/2815 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/92

摘要： The invention provides therapeutic humanized anti-HERV-K antibodies, CAR, or a fusion thereof consisting of a hispecific T ceil engager (BiTE) FOR CD3 and CDS, a DNA-encoded BiTE (DBiTE), or an antibody-drug conjugate (ADC). The invention also relates to peptides, proteins, nucleic acids, and cells for use in immunotherapeutic methods. In particular, the invention relates to the immunotherapy of cancer peptides bound to molecules of the MHC, or peptides as such, which can also be targets of antibodies and other binding molecules.

公开(公告)号：US20240024476A1

公开(公告)日：2024-01-25

申请号：US18260376

申请日：2022-01-06

申请人： Innovative Cellular Therapeutics Holdings, Ltd. ,  Innovative Cellular Therapeutics, Inc.

发明人： Chengfei Pu ,  Zhiyuan Cao ,  Xiaogang Shen ,  Wensheng Wang ,  Beibei Jia ,  Dongqi Chen ,  Xiaoqiang Xu ,  Xudong Tang ,  Wei Ding ,  Xianyang Jiang ,  Yuzhe Peng ,  Guiting Han ,  Le Tian ,  Zhao Wu ,  Lei Xiao

IPC分类号： A61K39/00 ,  C07K14/725 ,  C12N5/0783 ,  C07K16/30 ,  C07K16/28 ,  C07K16/18 ,  C07K16/40 ,  A61P35/00

CPC分类号： A61K39/4631 ,  C07K14/7051 ,  C12N5/0636 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/2875 ,  C07K16/2803 ,  C07K16/28 ,  C07K16/2851 ,  C07K16/18 ,  C07K16/40 ,  A61P35/00 ,  A61K39/4611 ,  A61K39/4644 ,  A61K39/464474 ,  A61K39/464417 ,  A61K39/464402 ,  A61K39/464458 ,  A61K39/464411 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2317/622 ,  A61K2239/13 ,  C07K2317/31

摘要： The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. For example, the compositions include CAR T cells comprising an extracellular domain that binds FCR1, MSLN, GPC-3, ALPP, CD70, CLDN6, ROR1, CD205, ACPP, ADAM12, or CLDN18.2.

公开(公告)号：US20240207406A1

公开(公告)日：2024-06-27

申请号：US18556054

申请日：2022-04-18

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Cassian YEE ,  Ke PAN ,  Yulun CHIU

IPC分类号： A61K39/00 ,  A61K45/06 ,  C07K7/06 ,  C07K14/725 ,  C07K14/74 ,  C07K16/32 ,  C12N5/0783 ,  C12N15/115 ,  G01N33/569

CPC分类号： A61K39/4644 ,  A61K39/0011 ,  A61K39/4611 ,  A61K39/4632 ,  A61K45/06 ,  C07K7/06 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/32 ,  C12N5/0636 ,  C12N15/115 ,  G01N33/56966 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2318/00 ,  C07K2319/30 ,  C07K2319/32 ,  C12N2502/1121 ,  C12N2510/00

摘要： The current disclosure fulfills a need in the art by providing methods and compositions for treating and vaccinating individuals against cancer. Accordingly, aspects of the disclosure relate to an isolated peptide comprising at least 70% sequence identity to a peptide of SEQ ID NO: 1 or 2. In some embodiments, the peptide comprises at least 6 contiguous amino acids of a peptide of SEQ ID NO:1 or 2. Further aspects relate to pharmaceutical compositions comprising the isolated peptide, nucleic acids encoding the peptide, and expression vectors and host cells comprising the nucleic acids of the disclosure. Also provided is an in vitro isolated dendritic cell comprising a peptide, nucleic acid, or expression vector of the disclosure.

公开(公告)号：US20240108722A1

公开(公告)日：2024-04-04

申请号：US18261765

申请日：2022-01-18

申请人： Kyle PEDRO ,  James STORER ,  Jan TER MEULEN ,  OBSIDIAN THERAPEUTICS, INC.

发明人： Kyle Pedro ,  James Alexander Storer ,  Jan ter Meulen ,  Rachel Burga ,  Mithun Khattar ,  Michelle Ols ,  Jeremy Tchaicha ,  Shyamsundar Subramanian

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/54 ,  C12N5/0783 ,  C12N15/86

CPC分类号： A61K39/4611 ,  A61K39/4632 ,  A61K39/4644 ,  A61P35/00 ,  C07K14/5443 ,  C12N5/0636 ,  C12N15/86 ,  A61K2039/5156 ,  C12N2501/2321 ,  C12N2501/599 ,  C12N2502/30 ,  C12N2510/00 ,  C12N2740/15043

摘要： Provided herein are tumor-infiltrating lymphocytes (TILs) engineered to express a membrane-bound interleukin 15 (mbIL15). The mbIL15 TILs can be expanded in vitro using arapid expansion protocol without the use of exogenous interleukin 2 (IL2) and can be used in adoptive cell therapy without concomitant use of an exogenous cytokine such as IL2. The TIL can be further engineered such that the mbIL15 is operably linked to one or more drug responsive domains (DRDs), polypeptides that can regulate the abundance and/or activity of the IL15 upon binding of the DRD with a ligand. Also provided herein are components for making the modified TILs and methods for making and using the modified TILs.

公开(公告)号：US20240100161A1

公开(公告)日：2024-03-28

申请号：US18018685

申请日：2021-07-30

申请人： THE FRANCIS CRICK INSTITUTE LIMITED

发明人： Caetano REIS E SOUSA ,  Johnathan Anias CANTON ,  Conor Maurice HENRY ,  Hanna BLEES

IPC分类号： A61K39/00 ,  C07K14/705 ,  C07K16/40

CPC分类号： A61K39/4633 ,  A61K39/4614 ,  A61K39/4622 ,  A61K39/4644 ,  C07K14/7056 ,  C07K16/40 ,  C07K2319/03

摘要： The present invention relates to chimeric receptors capable of facilitating cross-presentation (XP) of antigens, and methods of doing the same.

公开(公告)号：US20240058384A1

公开(公告)日：2024-02-22

申请号：US18501604

申请日：2023-11-03

申请人： SENTI BIOSCIENCES, INC.

发明人： Marcela Guzman Ayala

IPC分类号： A61K35/17 ,  C07K16/30 ,  A61P35/00 ,  A61K39/00

CPC分类号： A61K35/17 ,  C07K16/303 ,  A61P35/00 ,  A61K39/4611 ,  A61K39/4644 ,  A61K39/4613 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/53 ,  A61K2239/13

摘要： The present disclosure provides compositions and methods related to chimeric antigen receptors (CARs). In particular, the present disclosure provides CAR-based immunotherapeutic compositions that target tumor cells expressing glypican-3 (GPC3) for the treatment and prevention of cancer.

公开(公告)号：US20230398061A1

公开(公告)日：2023-12-14

申请号：US18249708

申请日：2021-10-20

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Abigail Kate GROSSKOPF ,  Eric Andrew APPEL ,  Crystal MACKALL ,  Louai LA-BANIEH

IPC分类号： A61K9/00 ,  A61K47/66 ,  A61K39/00 ,  A61K38/19 ,  A61K47/36 ,  A61K47/34

CPC分类号： A61K9/0024 ,  A61K47/66 ,  A61K39/4611 ,  A61K39/4631 ,  A61K38/19 ,  A61K47/36 ,  A61K47/34 ,  A61K39/4644 ,  A61K39/464411 ,  A61K39/4622 ,  A61K39/4613

摘要： An immunotherapy delivery system includes a hydrogel with an immunomodulatory cargo including cells encapsulated in the hydrogel, a cell adhesion motif in the hydrogel configured to reversibly adhere to and release the cells, and an immunomodulatory cargo encapsulated in the hydrogel. The hydrogel includes a polymer non-covalently crossed-linked with a plurality of nanoparticles.